The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
 
Kerry Anne Rogers
Consulting or Advisory Role - Acerta Pharma
Research Funding - Abbvie; Genentech
 
Philip A. Thompson
Consulting or Advisory Role - Abbvie (Inst); Genentech (Inst); Gilead Sciences (Inst); Pharmacyclics (Inst)
Speakers' Bureau - Abbvie; Genentech
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; Genentech; Gilead Sciences; Pharmacyclics
 
John Nathan Allan
Consulting or Advisory Role - Abbvie; Bayer; Genentech; Pharmacyclics; Sunesis Pharmaceuticals; Verastem
Travel, Accommodations, Expenses - Abbvie; Bayer; Genentech; Pharmacyclics; Sunesis Pharmaceuticals; Verastem
 
Morton Coleman
Stock and Other Ownership Interests - Gilead Sciences; Immunomedics
Consulting or Advisory Role - Celgene; Gilead Sciences; Pharmacyclics
Speakers' Bureau - Gilead Sciences; Janssen; Pharmacyclics
Research Funding - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Millenium Pharamceuticals; Pharmacyclics
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Celgene; Genentech; Pharmacyclics; TG Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Bruce D. Cheson
Consulting or Advisory Role - Abbvie; Acerta Pharma; Bayer; Morphosys; Pharmacyclics/Janssen; Roche/Genentech; Sunesis Pharmaceuticals; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Gilead Sciences (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
 
Raquel Izumi
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma
Consulting or Advisory Role - Trigemina
Patents, Royalties, Other Intellectual Property - Patents pending for Acerta Pharma
 
Melanie M. Frigault
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - MET mutation that confers sensitivity to a selective MET inhibitor
Travel, Accommodations, Expenses - AstraZeneca
 
Cheng Seok Quah
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma
 
Rakesh K. Raman
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma/AstraZeneca
 
Min Hui Wang
Employment - Acerta Pharma
Stock and Other Ownership Interests - AstraZeneca; Gilead Sciences
 
Thomas J. Kipps
Employment - Moores Cancer Center
Honoraria - Pharmacyclics/ AbbVie/ Janssen/ Celgene/Genentech/ Roche/ Gilead/ Dava Oncology
Consulting or Advisory Role - AbbVie/ Pharmacyclics/ Celgene/ Genentech/ Roche/ Leukemia / Janssen/ Dava Oncology/ Gilead
Speakers' Bureau - Verastem/Pharmacyclics
Travel, Accommodations, Expenses - Travel/ Honoraria covered by the companies below